SCHEMBL17830757

SCHEMBL17830757

CCCCn1c(=O)oc2cc(Cl)ccc21

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 2/20 0.54
HSD17B10 Q99714 2/20 0.54
LMNA P02545 1/20 0.54
CYP3A4 P08684 1/20 0.54
HPGD P15428 1/20 0.54
PIK3CB P42338 1/20 0.54
KMT2A Q03164 1/20 0.53
TMEM97 Q5BJF2 3/20 0.52
TP53 P04637 1/20 0.50
POLB P06746 1/20 0.50
MAPT P10636 1/20 0.50
KMO O15229 1/20 0.50
SIGMAR1 Q99720 1/20 0.49
THRB P10828 1/20 0.49
IDO1 P14902 2/20 0.49
ALDH1A1 P00352 2/20 0.49
NPSR1 Q6W5P4 1/20 0.49
NOS3 P29474 1/20 0.47
NOS1 P29475 1/20 0.47
NOS2 P35228 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16366709 0.96 TMEM97 (0.54) TDP1HSD17B10LMNACYP3A4HPGD
SCHEMBL3028907 0.87 PIK3CB (0.55) TDP1HSD17B10LMNACYP3A4HPGD
SCHEMBL14044191 0.84 LMNA (0.59) TDP1HSD17B10LMNACYP3A4HPGD
SCHEMBL3031599 0.82 TMEM97 (0.55) TMEM97
SCHEMBL17817481 0.80 LMNA (0.47) TDP1HSD17B10LMNACYP3A4HPGD
SCHEMBL10991734 0.80 IDO1 (0.54) TDP1HSD17B10LMNACYP3A4HPGD
SCHEMBL4423635 0.79 TP53 (0.63) TDP1HSD17B10LMNACYP3A4HPGD
SCHEMBL10987080 0.78 TDP1 (0.55) TDP1HSD17B10LMNACYP3A4HPGD
SCHEMBL10284153 0.78 ALDH1A1 (0.78) LMNAHPGDTP53MAPTALDH1A1
SCHEMBL22819341 0.78 P2RX3 (0.54) TDP1HSD17B10LMNACYP3A4HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9943506-B2 BCL6 inhibitors as anticancer agents CORNELL UNIVERSITY (US) 2018-04-17 US disclosed
US-20160166549-A1 BCL6 INHIBITORS AS ANTICANCER AGENTS CORNELL UNIVERSITY 2016-06-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160166549-A1 BCL6 INHIBITORS AS ANTICANCER AGENTS BCL6, BCL6B, BAZ2A TDP1 2505/4885HSD17B10 2511/4885LMNA 3890/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.